nifedipine has been researched along with Alzheimer Disease in 22 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine." | 9.27 | Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018) |
| "Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months." | 7.74 | Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008) |
| "Background Hypertension is common among patients with Alzheimer disease." | 6.90 | Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019) |
| "Nilvadipine treatment lowered systolic blood pressure (Δ=-11." | 6.90 | Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019) |
| "This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine." | 5.27 | Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018) |
| "In patients with hypertension and dementia, nifedipine was associated with increased mortality risk (aHR 1." | 4.02 | Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study. ( Eriksdotter, M; Garcia-Ptacek, S; Kalar, I; Kramberger, MG; Schwertner, E; Secnik, J; von Euler, M; Winblad, B; Xu, H, 2021) |
| "Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months." | 3.74 | Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008) |
| "Background Hypertension is common among patients with Alzheimer disease." | 2.90 | Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019) |
| "Nilvadipine treatment lowered systolic blood pressure (Δ=-11." | 2.90 | Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019) |
| "Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients." | 2.76 | Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. ( Abdullah, L; Crawford, F; Kennelly, SP; Kenny, RA; Lawlor, BA; Mathura, V; Mullan, M; Paris, D; Parish, J, 2011) |
| "He was diagnosed as having early Alzheimer's disease, in addition to hypertension and type II diabetes mellitus." | 1.35 | [A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists]. ( Akai, T; Hanyu, H; Iwamoto, T; Sakurai, H; Sato, T; Takasaki, A, 2008) |
| "The development of Alzheimer's disease (AD) is generally thought to correlate with cerebral accumulation of Abeta." | 1.32 | Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. ( Crawford, F; Crescentini, R; Humphrey, J; Mullan, M; Paris, D; Patel, N; Quadros, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| de Los Ríos, C | 4 |
| Egea, J | 3 |
| Marco-Contelles, J | 2 |
| León, R | 2 |
| Samadi, A | 1 |
| Iriepa, I | 2 |
| Moraleda, I | 2 |
| Gálvez, E | 1 |
| García, AG | 2 |
| López, MG | 2 |
| Villarroya, M | 2 |
| Romero, A | 2 |
| González-Muñoz, GC | 1 |
| Arce, MP | 1 |
| López, B | 1 |
| Pérez, C | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Conde, S | 1 |
| Rodríguez-Franco, MI | 1 |
| Gonzalez, D | 1 |
| Arribas, RL | 3 |
| Viejo, L | 1 |
| Lajarin-Cuesta, R | 1 |
| Bisi, A | 1 |
| Micucci, M | 1 |
| Budriesi, R | 1 |
| Feoli, A | 1 |
| Castellano, S | 1 |
| Belluti, F | 1 |
| Gobbi, S | 1 |
| Rampa, A | 1 |
| Malek, R | 1 |
| Palomino-Antolin, A | 1 |
| Totoson, P | 1 |
| Demougeot, C | 1 |
| Kobrlova, T | 1 |
| Soukup, O | 1 |
| Diez-Iriepa, D | 1 |
| Godyń, J | 1 |
| Panek, D | 1 |
| Malawska, B | 1 |
| Głuch-Lutwin, M | 1 |
| Mordyl, B | 1 |
| Siwek, A | 1 |
| Chabchoub, F | 1 |
| Kiec-Kononowicz, K | 1 |
| Ismaili, L | 1 |
| de Heus, RAA | 3 |
| Olde Rikkert, MGM | 4 |
| Tully, PJ | 1 |
| Lawlor, BA | 4 |
| Claassen, JAHR | 3 |
| Dyer, AH | 1 |
| Murphy, C | 2 |
| Segurado, R | 4 |
| Lawlor, B | 5 |
| Kennelly, SP | 2 |
| Kalar, I | 1 |
| Xu, H | 1 |
| Secnik, J | 1 |
| Schwertner, E | 1 |
| Kramberger, MG | 1 |
| Winblad, B | 1 |
| von Euler, M | 1 |
| Eriksdotter, M | 1 |
| Garcia-Ptacek, S | 1 |
| Kennelly, S | 4 |
| Howard, R | 3 |
| Pasquier, F | 3 |
| Börjesson-Hanson, A | 2 |
| Tsolaki, M | 3 |
| Lucca, U | 3 |
| Molloy, DW | 1 |
| Coen, R | 3 |
| Riepe, MW | 1 |
| Kálmán, J | 3 |
| Kenny, RA | 5 |
| Cregg, F | 3 |
| O'Dwyer, S | 3 |
| Walsh, C | 3 |
| Adams, J | 3 |
| Banzi, R | 3 |
| Breuilh, L | 3 |
| Daly, L | 3 |
| Hendrix, S | 1 |
| Aisen, P | 1 |
| Gaynor, S | 3 |
| Sheikhi, A | 1 |
| Taekema, DG | 1 |
| Verhey, FR | 1 |
| Nemni, R | 1 |
| Nobili, F | 1 |
| Franceschi, M | 1 |
| Frisoni, G | 1 |
| Zanetti, O | 1 |
| Konsta, A | 1 |
| Anastasios, O | 1 |
| Nenopoulou, S | 1 |
| Tsolaki-Tagaraki, F | 1 |
| Pakaski, M | 1 |
| Dereeper, O | 1 |
| de la Sayette, V | 1 |
| Sénéchal, O | 1 |
| Lavenu, I | 1 |
| Devendeville, A | 1 |
| Calais, G | 1 |
| Crawford, F | 6 |
| Mullan, M | 6 |
| Donders, R | 2 |
| Santoso, AMM | 1 |
| de Jong, DLK | 1 |
| Rijpma, A | 1 |
| Günther, M | 1 |
| van Osch, MJP | 1 |
| Riepe, M | 2 |
| Wallin, A | 2 |
| Borjesson, A | 1 |
| Molloy, W | 2 |
| Olde Rikkert, M | 2 |
| Lovell, MA | 1 |
| Lynn, BC | 1 |
| Fister, S | 1 |
| Bradley-Whitman, M | 1 |
| Murphy, MP | 1 |
| Beckett, TL | 1 |
| Norris, CM | 1 |
| Meulenbroek, O | 1 |
| de Jong, D | 1 |
| van Spijker, G | 1 |
| Abdullah, L | 3 |
| Sato, T | 1 |
| Hanyu, H | 1 |
| Akai, T | 1 |
| Takasaki, A | 1 |
| Sakurai, H | 1 |
| Iwamoto, T | 1 |
| Mathura, V | 2 |
| Luis, CA | 1 |
| Mouzon, B | 1 |
| Paris, D | 2 |
| Parish, J | 1 |
| Peers, C | 1 |
| Green, KN | 1 |
| Boyle, JP | 1 |
| Quadros, A | 1 |
| Humphrey, J | 1 |
| Patel, N | 1 |
| Crescentini, R | 1 |
| Matsuda, H | 1 |
| Araki, N | 1 |
| Kuji, I | 1 |
| Ohkubo, T | 1 |
| Imabayashi, E | 1 |
| Shimazu, K | 1 |
| Lee, YJ | 1 |
| Jy, W | 1 |
| Horstman, LL | 1 |
| Janania, J | 1 |
| Reyes, Y | 1 |
| Kelley, RE | 1 |
| Ahn, YS | 1 |
| Wang, SJ | 1 |
| Huang, CC | 1 |
| Gean, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for nifedipine and Alzheimer Disease
| Article | Year |
|---|---|
Blood Pressure Variability and Progression of Clinical Alzheimer Disease.
Topics: Aged; Alzheimer Disease; Antihypertensive Agents; Blood Pressure Determination; Cognition Disorders; | 2019 |
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili | 2020 |
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease | 2018 |
Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2019 |
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cerebrovascular Circulation; D | 2019 |
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Double-Blind Method; Europe; F | 2014 |
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flo
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E3; Biomarkers; Calcium Channel Blockers; | 2016 |
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Apolipoprotein E4; Cognition; C | 2012 |
Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Blood Pressure; Female; Humans; | 2011 |
13 other studies available for nifedipine and Alzheimer Disease
| Article | Year |
|---|---|
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calc | 2010 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca
Topics: Alkaloids; Alzheimer Disease; Calcium; Calcium Channel Blockers; Cell Line, Tumor; Humans; Indole Al | 2018 |
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Calcium Channels, N-Type; Glycogen Synthase Kinase 3 beta; Humans; Maleimides; Po | 2019 |
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Cholinesterase Inhibitors; Humans; Memory Diso | 2019 |
Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study.
Topics: Alzheimer Disease; Amlodipine; Brain Ischemia; Calcium Channel Blockers; Humans; Hypertension; Ische | 2021 |
A Novel Small Molecule Modulator of Amyloid Pathology.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antipsyc | 2016 |
[A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists].
Topics: Aged; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Calcium | 2008 |
Amyloid peptide-mediated hypoxic regulation of Ca2+ channels in PC12 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium Channel Blockers; Calcium Channels; Calci | 2003 |
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcium Channel B | 2004 |
Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Cerebrovascular Circulation; Cysteine | 2008 |
Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias.
Topics: Adult; Aged; Alzheimer Disease; Blood Platelets; Cerebral Infarction; Dementia, Multi-Infarct; Femal | 1993 |
Investigations on the mechanism of tetrahydro-9-aminoacridine-induced presynaptic inhibition in the rat amygdala.
Topics: 4-Aminopyridine; Alzheimer Disease; Amygdala; Animals; Baclofen; Dose-Response Relationship, Drug; M | 1996 |